Dapagliflozin for anemia in kidney disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with chronic kidney disease stage 3 or 4 (moderate to severe kidney damage).
- You have anemia caused by your kidney disease, and your hemoglobin level is below 11.5 g/dL.
- You are already receiving medication (like epoetin or darbepoetin) to treat your anemia.
- Your anemia is not due to other causes like pernicious anemia, thalassemia, sickle cell disease, or bone marrow problems.
- You have not had a heart attack, stroke, or severe heart failure in the last 6 months, and you do not have active cancer or a recent cancer history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This trial tests whether dapagliflozin, a diabetes medication, can safely increase red blood cell counts and reduce the need for transfusions in patients with lower-risk myelodysplastic syndromes (a blood disorder where the bone marrow doesn't make enough healthy blood cells). The goal is to help patients with anemia feel less tired and avoid frequent blood transfusions.
This trial studies whether dapagliflozin (a heart-failure medicine) can improve anemia in people with heart failure. It may help explain why some patients feel better and how anemia changes when this medicine is used.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This study tests if a once-daily medication called dapagliflozin (Forxiga) can reduce inflammation and improve iron use and red blood cell production in people with both type 2 diabetes and chronic kidney disease. It may help protect your kidneys and overall health.
Hear when a new Chronic Kidney Disease(CKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.